Last reviewed · How we verify
oxetacaine
oxetacaine is a Small molecule drug developed by MEDA Pharma GmbH & Co. KG. It is currently in discontinued development.
Oxetacaine is a small molecule local anesthetic. It is used orally for the relief of pain associated with conditions such as peptic ulcer disease and esophagitis.
At a glance
| Generic name | oxetacaine |
|---|---|
| Sponsor | MEDA Pharma GmbH & Co. KG |
| Target | Sodium channel alpha subunits; brain (Types I, II, III) |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- oxetacaine CI brief — competitive landscape report
- oxetacaine updates RSS · CI watch RSS
- MEDA Pharma GmbH & Co. KG portfolio CI
Frequently asked questions about oxetacaine
What is oxetacaine?
oxetacaine is a Small molecule drug developed by MEDA Pharma GmbH & Co. KG.
Who makes oxetacaine?
oxetacaine is developed by MEDA Pharma GmbH & Co. KG (see full MEDA Pharma GmbH & Co. KG pipeline at /company/meda-pharma-gmbh-co-kg).
What development phase is oxetacaine in?
oxetacaine is in discontinued.
What does oxetacaine target?
oxetacaine targets Sodium channel alpha subunits; brain (Types I, II, III).
Related
- Target: All drugs targeting Sodium channel alpha subunits; brain (Types I, II, III)
- Manufacturer: MEDA Pharma GmbH & Co. KG — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing